Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04976205
Other study ID # 2928
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 15, 2021
Est. completion date September 2024

Study information

Verified date September 2022
Source Istituto Clinico Humanitas
Contact Pietro Mancosu, PhD
Phone +390282248529
Email pietro.mancosu@humanitas.it
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Total Body Irradiation (TBI) was shown to help in providing immunosuppression that facilitates the donor transplant acceptance. Randomized trials demonstrated that conditioning regimens to bone marrow transplantation (BMT) including TBI have produced better survival rates than chemo-only regimens. The TBI target is represented by the whole BM, and eventually the whole lymphatic system, liver, spleen. The increased life expectancy revealed the occurrence of important toxicities because of full doses received by organs at risk (OARs) and this limited the use of TBI. Many groups have explored the possibility of sophisticated techniques for reducing the dose to healthy tissues while increasing the dose to the BM. These newer approaches aim to generate total marrow (lymph-node) irradiation (TMI/TMLI), sparing as much as possible non-skeletal and non-lymphoid structures. Actually, the time required to optimize a TMI/TMLI plan is 10 days. Therefore, the simulation Computed Tomography (CT) is performed many days before the BMT. Furthermore, the lymph-nodes are defined only on CT images.


Description:

Total Body Irradiation (TBI) was shown to help in providing immunosuppression that facilitates the donor transplant acceptance. Moreover, TBI plays a role in the annihilation of malignant cells, and may also deplete normal hematopoietic stem cells, thus helping the donor marrow cells to repopulate the bone marrow (BM). Randomized trials demonstrated that conditioning regimens to BMT including TBI have produced better survival rates than chemo-only regimens. The TBI target is represented by the whole BM, and eventually the whole lymphatic system, liver, spleen. Usually, a very simple geometry is adopted, with patient positioned on a dedicated couch at 3-4 meters away from the linear accelerator to fully cover the target with a single beam, avoiding field junctions. The increased life expectancy revealed the occurrence of important toxicities because of full doses received by organs at risk (OARs) and this limited the use of TBI as stated by the 2018 ILGROG guidelines. Many groups have, therefore, explored the possibility of sophisticated techniques for reducing the dose to healthy tissues while increasing the dose to the BM. These newer approaches aim to generate total marrow (lymph-node) irradiation (TMI/TMLI), sparing as much as possible non-skeletal and non-lymphoid structures. Preliminary clinical data on phase I/II trials support the use of TMI/TMLI as part of conditioning for BMT for relapsed-refractory acute leukemia patients and multiple myeloma. However, TMI/TMLI adoption is still very limited to few skilled hospitals due to the extreme difficulty in the planning that needs many days. The evaluation of TMI/TMLI with Volumetric Modulated Arc Therapy (VMAT) was started in our institute in 2009 and we treated around 90 patients in 10 years. VMAT-TMI/TMLI requires multiple arcs from isocenters with different positions to fully include the patient length. Therefore, many field junctions between arcs with different isocenters should be managed. Furthermore, the CT length does not allow to acquire the patient in a single CT scan. Two CT series must be acquired and co-registered. Actually, the time required to optimize a TMI/TMLI plan is 10 days. Therefore, the simulation Computed Tomography (CT) is performed many days before the BMT. Furthermore, the lymph-nodes are defined only on CT images. Deep learning (DL) artificial intelligence (AI) algorithms in medical imaging and RT are rapidly expanding. DL focused on lesion detection and classification by features extraction. Image segmentations using fully convolutional network (FCN), holistically nested network (HNN) or other customized network architectures were implemented in many regions. Over the past decades, the use of magnetic resonance imaging (MRI) to support RT has increased. MRI provides excellent soft-tissue imaging that could improve the target definition. The lymph-nodes contouring, based on MRI, will result in smaller target, enabling a better sparing of healthy tissues. Moreover, MRI significantly reduces inter/intra-observer contouring variability. At this aim, new generation MRI consoles with larger bore size, flat tabletops and dedicated imaging protocols with reduced image distortion to <1 mm were developed. Moreover, newly developed gradient-echo 3D sequences, and dedicated coils, can be used for producing a whole body WB-MRI acquisition in a few minutes. Furthermore, synthetic CT from MRI was proposed and implemented in some regions (i.e. brain and prostate) to substitute the CT for providing electron density information for dose planning calculation.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date September 2024
Est. primary completion date September 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Written, signed informed consent - Adult patients aged =18 years - Diagnosis of Hematological disease - Eligibility for allogeneic stem cell transplantation as center guidelines - TMI/TLI as part of the conditioning regimen Exclusion Criteria: - Conditioning regimen including only chemotherapeutic agents

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
Total Marrow (Lymph-node) Irradiation
To the standard procedure for TMI/TMLI target definition, based on simulation WB-CT acquired 10/15 days before BMT, we acquire: WB- magnetic resonance imaging (MRI) the same day of the simulation WB-CT. A verification WB-CT will be performed 3/4 days before the delivery. Plans will be optimized with Volumetric Modulated Arc Therapy (VMAT) technique.

Locations

Country Name City State
Italy IRCCS Humanitas Research Center Rozzano Milano

Sponsors (1)

Lead Sponsor Collaborator
Istituto Clinico Humanitas

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Reduction of Lymph nodes target volume thanks to WB-MRI The PTV_LN volumes generated on the Simulation WB-MRI and on the Simulation WB-CT will be compared. 3 years
Secondary Doses calcuated on CT performed at day -3 (4) to the BMT To evaluate the dosimetric changes that occurs in the days between the simulation and the delivery.
The RT plan is defined on a simulation CT perfomed at -15 days. A second CT is performed at day -3 (4) to the BMT. The RT plan is recalculated on the second CT. The PTV volume receiving 95% of doses will be recorded.
3 years
See also
  Status Clinical Trial Phase
Completed NCT02660281 - URMC Related Haplo-identical Donor BMT Phase 1
Completed NCT03004261 - CMV-CTL for the Treatment of CMV Infection After HSCT Phase 4
Recruiting NCT01684189 - Registry of Febrile Neutropenia and Invasive Fungal Infections N/A
Completed NCT02447237 - Randomized Trial:the Effect of Liquid Food on the Intake of Energy and Protein in Malignant Hematologic Patients N/A
Not yet recruiting NCT06143098 - Some Hematological Profile in Children With Chronic Kidney Disease
Not yet recruiting NCT06050798 - Hematological Disorder in Patients With Angiodysplasia
Active, not recruiting NCT02158858 - A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis Phase 1/Phase 2
Enrolling by invitation NCT02456818 - Assessing the Effect of Contact Isolation on Nosocomial Colonization With ESBL-EC in German Hematology/Oncology Wards N/A
Recruiting NCT05727917 - Hetrombopag for the Enhancement of Platelet Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation N/A
Completed NCT03355742 - XIENCE 28 Global Study N/A
Recruiting NCT00883961 - Exercise Following Autologous Peripheral Blood Stem Cell Transplantation Phase 3
Completed NCT00820508 - Safety and Tolerability of CHR-2845 to Treat Haematological Diseases or Lymphoid Malignancies Phase 1
Terminated NCT01359254 - Cord Blood Transplantation for Patients With Cancer Phase 2